Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2007-04-12 20:05:47 UTC |
---|
Update Date | 2021-09-14 15:40:23 UTC |
---|
HMDB ID | HMDB0006001 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | 3'-Hydroxystanozolol |
---|
Description | 3'-Hydroxystanozolol is a metabolite of stanozolol. Stanozolol has the potential for misuse as an anabolic steroid in horse racing. Stanozolol is an anabolic steroid illicitly used for growth promoting purposes in animal production. For reasons of public health the use of anabolic steroids as growth promoters is officially banned in Europe in animals intended for consumption. Stanozolol is a synthetic anabolic androgenic steroid often abused in sports to enhance performance. Doping control screening for the analysis of anabolic steroids in human urine or the detection of anabolic steroid residues in cattle's urine is achieved using liquid and gas chromatography time-of-flight mass spectrometry, liquid chromatography-tandem mass spectrometry or through a combination of liquid chromatography/tandem mass spectrometry and gas chromatography/mass spectrometry. Androgenic anabolic steroids are defined as natural, synthetic or semi-synthetic drugs chemicals derived from testosterone, used with the aim to improve physical performance by increasing both muscle strength and mass. Despite their reported toxicological effects on the cardiovascular, hepatic and neuro-endocrine systems, the AAS have been extensively used in sports activities. |
---|
Structure | [H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=C(C[C@]12C)C(=O)NN3 InChI=1S/C21H32N2O2/c1-19-11-14-17(22-23-18(14)24)10-12(19)4-5-13-15(19)6-8-20(2)16(13)7-9-21(20,3)25/h12-13,15-16,25H,4-11H2,1-3H3,(H2,22,23,24)/t12-,13+,15-,16-,19-,20-,21-/m0/s1 |
---|
Synonyms | Value | Source |
---|
17alpha-Methyl-17beta-hydroxy-5alpha-androstano(3,2-c)pyrazole | MeSH | 3'-Hydroxystanazolol | HMDB | (5 ,17 )-1',2'-dihydro-17-Hydroxy-17-methyl-5'H-androst-2-eno[3,2-c]pyrazol-5'-one | HMDB | 3'-Hydroxystanozolol | MeSH |
|
---|
Chemical Formula | C21H32N2O2 |
---|
Average Molecular Weight | 344.491 |
---|
Monoisotopic Molecular Weight | 344.246378278 |
---|
IUPAC Name | (1S,2S,10S,13R,14S,17S,18S)-17-hydroxy-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁸]icos-4(8)-en-5-one |
---|
Traditional Name | (1S,2S,10S,13R,14S,17S,18S)-17-hydroxy-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁸]icos-4(8)-en-5-one |
---|
CAS Registry Number | 125709-39-9 |
---|
SMILES | [H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=C(C[C@]12C)C(=O)NN3 |
---|
InChI Identifier | InChI=1S/C21H32N2O2/c1-19-11-14-17(22-23-18(14)24)10-12(19)4-5-13-15(19)6-8-20(2)16(13)7-9-21(20,3)25/h12-13,15-16,25H,4-11H2,1-3H3,(H2,22,23,24)/t12-,13+,15-,16-,19-,20-,21-/m0/s1 |
---|
InChI Key | SWPAIUOYLTYQKK-YEZTZDHTSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as estrane steroids. These are steroids with a structure based on the estrane skeleton. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Estrane steroids |
---|
Direct Parent | Estrane steroids |
---|
Alternative Parents | |
---|
Substituents | - Estrane-skeleton
- Hydroxysteroid
- 17-hydroxysteroid
- Pyrazolinone
- Azole
- Cyclic alcohol
- Pyrazole
- Tertiary alcohol
- Vinylogous amide
- Heteroaromatic compound
- Lactam
- Organoheterocyclic compound
- Azacycle
- Organopnictogen compound
- Alcohol
- Organooxygen compound
- Organonitrogen compound
- Organic oxide
- Organic nitrogen compound
- Organic oxygen compound
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times UnderivatizedChromatographic Method | Retention Time | Reference |
---|
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.86 minutes | 32390414 | Predicted by Siyang on May 30, 2022 | 12.9254 minutes | 33406817 | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.95 minutes | 32390414 | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2055.9 seconds | 40023050 | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 247.2 seconds | 40023050 | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 192.0 seconds | 40023050 | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 160.9 seconds | 40023050 | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 337.9 seconds | 40023050 | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 529.8 seconds | 40023050 | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 502.9 seconds | 40023050 | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 129.2 seconds | 40023050 | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1020.4 seconds | 40023050 | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 481.1 seconds | 40023050 | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1120.3 seconds | 40023050 | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 359.0 seconds | 40023050 | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 423.9 seconds | 40023050 | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 257.2 seconds | 40023050 | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 343.9 seconds | 40023050 | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 7.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
3'-Hydroxystanozolol,1TMS,isomer #1 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)[NH][NH]C3=O | 3245.3 | Semi standard non polar | 33892256 | 3'-Hydroxystanozolol,1TMS,isomer #2 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O)[NH]N([Si](C)(C)C)C3=O | 3199.8 | Semi standard non polar | 33892256 | 3'-Hydroxystanozolol,1TMS,isomer #3 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O)N([Si](C)(C)C)[NH]C3=O | 3230.1 | Semi standard non polar | 33892256 | 3'-Hydroxystanozolol,2TMS,isomer #1 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)[NH]C3=O | 3261.2 | Semi standard non polar | 33892256 | 3'-Hydroxystanozolol,2TMS,isomer #1 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)[NH]C3=O | 3332.0 | Standard non polar | 33892256 | 3'-Hydroxystanozolol,2TMS,isomer #1 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)[NH]C3=O | 3504.2 | Standard polar | 33892256 | 3'-Hydroxystanozolol,2TMS,isomer #2 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)[NH]N([Si](C)(C)C)C3=O | 3246.7 | Semi standard non polar | 33892256 | 3'-Hydroxystanozolol,2TMS,isomer #2 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)[NH]N([Si](C)(C)C)C3=O | 3288.8 | Standard non polar | 33892256 | 3'-Hydroxystanozolol,2TMS,isomer #2 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)[NH]N([Si](C)(C)C)C3=O | 3526.8 | Standard polar | 33892256 | 3'-Hydroxystanozolol,2TMS,isomer #3 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O)N([Si](C)(C)C)N([Si](C)(C)C)C3=O | 3241.0 | Semi standard non polar | 33892256 | 3'-Hydroxystanozolol,2TMS,isomer #3 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O)N([Si](C)(C)C)N([Si](C)(C)C)C3=O | 3344.3 | Standard non polar | 33892256 | 3'-Hydroxystanozolol,2TMS,isomer #3 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O)N([Si](C)(C)C)N([Si](C)(C)C)C3=O | 3499.6 | Standard polar | 33892256 | 3'-Hydroxystanozolol,3TMS,isomer #1 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)N([Si](C)(C)C)C3=O | 3246.0 | Semi standard non polar | 33892256 | 3'-Hydroxystanozolol,3TMS,isomer #1 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)N([Si](C)(C)C)C3=O | 3299.7 | Standard non polar | 33892256 | 3'-Hydroxystanozolol,3TMS,isomer #1 | C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)N([Si](C)(C)C)C3=O | 3445.1 | Standard polar | 33892256 | 3'-Hydroxystanozolol,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)[NH][NH]5 | 3480.1 | Semi standard non polar | 33892256 | 3'-Hydroxystanozolol,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1[NH]C2=C(C[C@@]3(C)[C@@H](CC[C@@H]4[C@@H]3CC[C@@]3(C)[C@H]4CC[C@]3(C)O)C2)C1=O | 3418.7 | Semi standard non polar | 33892256 | 3'-Hydroxystanozolol,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N1[NH]C(=O)C2=C1C[C@@H]1CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3CC[C@]4(C)O)[C@@]1(C)C2 | 3431.7 | Semi standard non polar | 33892256 | 3'-Hydroxystanozolol,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)[NH]N5[Si](C)(C)C(C)(C)C | 3679.2 | Semi standard non polar | 33892256 | 3'-Hydroxystanozolol,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)[NH]N5[Si](C)(C)C(C)(C)C | 3860.7 | Standard non polar | 33892256 | 3'-Hydroxystanozolol,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)[NH]N5[Si](C)(C)C(C)(C)C | 3667.3 | Standard polar | 33892256 | 3'-Hydroxystanozolol,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)N([Si](C)(C)C(C)(C)C)[NH]5 | 3665.8 | Semi standard non polar | 33892256 | 3'-Hydroxystanozolol,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)N([Si](C)(C)C(C)(C)C)[NH]5 | 3798.6 | Standard non polar | 33892256 | 3'-Hydroxystanozolol,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)N([Si](C)(C)C(C)(C)C)[NH]5 | 3680.3 | Standard polar | 33892256 | 3'-Hydroxystanozolol,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N1C2=C(C[C@@]3(C)[C@@H](CC[C@@H]4[C@@H]3CC[C@@]3(C)[C@H]4CC[C@]3(C)O)C2)C(=O)N1[Si](C)(C)C(C)(C)C | 3643.5 | Semi standard non polar | 33892256 | 3'-Hydroxystanozolol,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N1C2=C(C[C@@]3(C)[C@@H](CC[C@@H]4[C@@H]3CC[C@@]3(C)[C@H]4CC[C@]3(C)O)C2)C(=O)N1[Si](C)(C)C(C)(C)C | 3849.5 | Standard non polar | 33892256 | 3'-Hydroxystanozolol,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N1C2=C(C[C@@]3(C)[C@@H](CC[C@@H]4[C@@H]3CC[C@@]3(C)[C@H]4CC[C@]3(C)O)C2)C(=O)N1[Si](C)(C)C(C)(C)C | 3662.4 | Standard polar | 33892256 | 3'-Hydroxystanozolol,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)N([Si](C)(C)C(C)(C)C)N5[Si](C)(C)C(C)(C)C | 3833.1 | Semi standard non polar | 33892256 | 3'-Hydroxystanozolol,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)N([Si](C)(C)C(C)(C)C)N5[Si](C)(C)C(C)(C)C | 4021.3 | Standard non polar | 33892256 | 3'-Hydroxystanozolol,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)N([Si](C)(C)C(C)(C)C)N5[Si](C)(C)C(C)(C)C | 3666.0 | Standard polar | 33892256 |
|
---|